A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Veracyte, Inc. VCYT

Mixed broader-coverage candidate · Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; De

On FrontierLab's discovery record since 2026-07-13 (5 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-21), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	17.3%
Gross margin	72.1%
Gross profits / assets	0.27
Rule of 40	34.3
Net margin	17%
Cash runway (months)	—
PEG	0.1
Price / sales	5.9

Quality checklist

~ Revenue growth — 17.3% (pass ≥ 20%)
~ Gross profits / assets — 0.27 (pass ≥ 0.33)
✓ Gross margin — 72.1% (pass ≥ 60%)
✓ Cash generation
~ Share dilution — 2.9%

Fundamentals — snapshot as of 2026-08-21

Stage	Established
Share issuance (YoY)	2.9% · modest issuance
Moat	—
TAM	—
P/E (trailing)	29.9
EPS (trailing)	$1.40
Burn multiple	—
Gross-margin trend (pts)	3.8
Cash / assets	0.33
Net debt / EBITDA	-2
Statements as of	Q2 FY2026 · filed 2026-07-31

Momentum context — a snapshot from 2026-08-21, not current

Price at surface	$41.79 (as of 2026-08-21)
52-week range	$28.25 – $60.91
% off 52-wk high	-31.4%
RSI (14)	34
Relative volume	0.7×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-21 (end-of-day). How grades are computed →